Webinar: FDA’s New Decentralized Trials Guidance: What Regulatory Professionals Need to Know
Tuesday, June 6, 2023, 12:00pm ET
See Ahead of the Curve.
Our team of nonpartisan experts, along with customizable, intelligent, analysis solutions clear a path through complex regulation, helping you accelerate action in your industry and improve business-critical outcomes.
What We Expect the FDA to do in June 2023
In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The goal: To allow regulatory professionals to better anticipate and prepare for upcoming events and catalysts.
FDA unveils long-awaited Patient Medication Information proposed rule
Since 2017, the FDA has been working on a proposal to create a new type of patient-focused labeling for certain outpatient drug products that would be specifically targeted for patient use. That proposed rule, which would establish Patient Medication Information (PMI) as a type of labeling, has now been published. But while the rule emphasizes a brief, patient-friendly approach, drug and biologics companies may find the proposal difficult to operationalize.
EU chemicals regulatory roundup for June 2023
This recurring feature pulls together relevant information from across European Union agencies and institutions to create an extensive list of the chemicals-related regulatory actions anticipated in the month ahead, including planned legislation, consultations, meetings, events, and more.
EPA lab contradicts previous study on PFAS in pesticide products
The Environmental Protection Agency has issued a report reviewing a 2022 study on per- and polyfluoroalkyl substances detected in pesticide products. The report contradicts the findings of the 2022 study, using both the method of testing in the study as well as the agency’s own test procedures.
Visibility into industry movements,
so you can keep up with regulation.
From biotechnology to agriculture, dietary supplements to nanomaterials, and legal and consulting regulations, AgencyIQ makes navigating through complex rules simple. Sources are tailored to your industry’s world, so you can stay plugged in to the regulatory landscape and clearly map out organizational success. Learn more about our regulatory intelligence solution below.
85+
Years of Combined Regulatory Experience
20+
Areas of Research Focus
Chemical
- Agriculture
- Automotive
- Chemical Management
- Emissions
- Energy
- Electronics
- Food Contact Materials
- Globally Harmonized System
- Hazardous Waste
- Hazardous Substances
- Household Products
- Occupational Exposure Limits
- Personal Products
- Pesticides
Life Sciences
- Advanced Therapies
- Biologics
- Blood Products
- Diagnostics
- Dietary Supplements
- Generics/Biosimilars
- Medical Devices
- OTC products
- Pharmaceuticals
Unparalleled Regulatory and Industry Expertise
Regulation is ever-evolving, but you can stay informed and focus your team.
A lack of internal resources and qualified hires can leave you shortsighted. Our team of credentialed experts are on hand offering customized insights from the latest research and reports to help you predict outcomes, act fast, and make an impact.
Essential Analysis and Insights
Get ahead of regulatory movement with concise, well-sourced analysis.
Daily, concise review and synthesis of research and updates help you gain clarity and understanding regarding what’s happening and why it’s important. With over 1,000 regulatory research analyses, ensure a full view of accurate, actionable insights.
Intelligent, Online Workspace
Move the needle on policy with a simple way to collaborate
AgencyIQ’s customizable dashboard and personalized research collection helps you track important content, and enables seamless sharing within your team. Collaboration and workflow tools on a single, holistic platform make it easy to accelerate action in your organization.
